دورية أكاديمية
Impact of Surgery and Chemotherapy on Metastatic Extrauterine Leiomyosarcoma
العنوان: | Impact of Surgery and Chemotherapy on Metastatic Extrauterine Leiomyosarcoma |
---|---|
المؤلفون: | Yoshinori Imura, Satoshi Takenaka, Hidetatsu Outani, Takaaki Nakai, Naohiro Yasuda, Sho Nakai, Toru Wakamatsu, Hironari Tamiya, Seiji Okada |
المصدر: | Current Oncology, Vol 29, Iss 4, Pp 2301-2311 (2022) |
بيانات النشر: | MDPI AG, 2022. |
سنة النشر: | 2022 |
المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
مصطلحات موضوعية: | metastatic extrauterine leiomyosarcoma, overall survival, metastasectomy, chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
الوصف: | Background: Few studies have described the characteristics and prognostic factors of patients with metastatic extrauterine leiomyosarcoma (euLMS). Therefore, we retrospectively investigated the clinicopathological features, clinical outcomes, and prognostic factors of patients with euLMS. Methods: We recruited 61 patients with metastatic euLMS treated from 2006 to 2020 and collected and statistically analyzed information on patient-, tumor-, and treatment-related factors. The median follow-up period was 21.1 months. Results: Sixty-one patients with euLMS and a median age of 59 years were included. Furthermore, their five-year overall survival (OS) rate was 38.3%. Univariate analysis revealed that primary tumor size >10 cm, synchronous metastasis, initial metastatic sites >1, and no metastasectomy with curative intent were significantly associated with poor OS rate. Multivariate analysis identified primary tumor size >10 cm as an independent prognostic factor for poor OS. Among 24 patients who received metastasectomy with curative intent, the interval from the initial diagnosis to development of metastasis ≤6 months was significantly correlated with unfavorable OS. Among 37 patients who did not receive metastasectomy, chemotherapy after metastasis development was significantly related to better OS. Conclusions: Complete metastasectomy should be considered for metastatic euLMS treatment. Moreover, chemotherapy could prolong survival in patients with metastasis who are ineligible for metastasectomy. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 1718-7729 1198-0052 |
Relation: | https://www.mdpi.com/1718-7729/29/4/187; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729 |
DOI: | 10.3390/curroncol29040187 |
URL الوصول: | https://doaj.org/article/84022c8882074a419af8d27849752875 |
رقم الأكسشن: | edsdoj.84022c8882074a419af8d27849752875 |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 17187729 11980052 |
---|---|
DOI: | 10.3390/curroncol29040187 |